

Patient Zero: Plague Idle is an idle / incremental outbreak builder where you create the perfect pathogen through mutation trees, global infection, long-term upgrades, and new pathogen unlocks. Turn the world into your lab.
Overview
Patient Zero: Plague Idle is an idle / incremental outbreak builder where you create the perfect pathogen through mutation trees, global infection, long-term upgrades, and new pathogen unlocks. Turn the world into your lab.
Description
Micro-scale evolution. Macro-scale extinction.
Patient Zero is an idle/incremental pandemic strategy where you engineer ever-evolving biological threats. As the architect of collapse, min-max your mutation layers to ensure the world succumbs to your design.
Master a progression cycle built for massive scaling:
Harvest: Gather Biomass to fuel expansion.
Automate: Maximize your infection per second (IPS).
Mutate: Spend Genetic Capital on synergistic evolution trees.
Transcend: Use Prestige Layers to unlock meta-progression and resilient strains.
Navigate a vast Mutation Tree where every choice impacts global power. Balance stealth with lethality to overcome medical research and trigger an unstoppable snowball effect across extreme climates.
Watch the map turn red as your creation collapses healthcare systems. Every region requires a specific strategic path to maximize infection yield and bypass localized defenses in real-time.
Pathogens: Master prestige mechanics for Viruses, Bacteria, Fungi, and Nanobots.
AFK Gains: Progress continues with substantial offline rewards.
Dynamic Meta: Adapt to news, lockdowns, and global cure efforts.
Can you engineer the ultimate extinction event? The evolution begins now.
Screenshots
Official
Official
Official
Official
Official
OfficialCommunity
Community
... no lists at all!
So what you may do right now is:
Gallery
Video
Patient Zero: Plague Idle
Ratings
Technical
Steam
Pricing
Store
Community
... no lists at all!
So what you may do right now is:
Gallery
... no screenshots at all!
So what you may do right now is:
No reviews yet.